ScholarLens Back to search
2018•Transplantation and Cellular TherapyOpen access

Pegfilgrastim (Neulasta®) Vs. Tbo-Filgrastim (Granix®) Post Autologous Transplant

Sarah Schmidt, Katherine Newman, Michael Machiorlatti, Sara K. Vesely, Jennifer Holter Chakrabarty, George B. Selby

Open full text 0 citations

Abstract

Background: Granulocyte colony stimulating factors (G-CSFs) are typically incorporated after stem cell infusion for autologous hematopoietic cell transplantation (HCT), while not absolutely necessary, G-CSF support has shown to decrease time to engraftment, shorten hospital length of stay and decrease neutropenic fever. With the approval of filgrastim-sndz (Zarxio®) and TBO-filgrastim (Granix®), drug cost has decreased compared to pegfilgrastim (Neulasta®) and filgrastim (Neupogen®). There have been few studies assessing the safety and efficacy in the transplant setting.

About this research paper

What this paper is about

Background: Granulocyte colony stimulating factors (G-CSFs) are typically incorporated after stem cell infusion for autologous hematopoietic cell transplantation (HCT), while not absolutely necessary, G-CSF support has shown to decrease time to engraftment, shorten hospital length of stay and decrease neutropenic fever. With the approval of filgrastim-sndz (Zarxio®) and TBO-filgrastim (Granix®), drug cost has decreased compared to pegfilgrastim (Neulasta®) and filgrastim (Neupogen®). There have been few studies assessing the safety and efficacy in the transplant setting.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: Granulocyte colony stimulating factors (G-CSFs) are typically incorporated after stem cell infusion for autologous hematopoietic cell transplantation (HCT), while not absolutely necessary, G-CSF support has shown to decrease time to engraftment, shorten hospital length of stay and decrease neutropenic fever. With the approval of filgrastim-sndz (Zarxio®) and TBO-filgrastim (Granix®), drug cost has decreased compared to pegfilgrastim (Neulasta®) and filgrastim (Neupogen®). There have been few studies assessing the safety and efficacy in the transplant setting.

Key concepts: Filgrastim, Pegfilgrastim, Medicine, Surgery, Granulocyte colony-stimulating factor, Hematopoietic stem cell transplantation, Transplantation, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Pegfilgrastim (Neulasta®) Vs. Tbo-Filgrastim (Granix®) Post Autologous Transplant — Research Paper | ScholarLens